Carmen’s Medicinals Launches New Product Line with Higher THC Concentration

By João R. Negromonte

Sponsored content by Carmen's Medicinals

Founded in 2018 in the USA, Carmen’s Medicinals emerged from the founder Juan Romero's love for his grandmother, who suffered from cancer. The mission was to develop and provide high-quality products, promoting access to cannabinoid therapy for all who need it. As a result, the company has become one of the market leaders, expanding its business to various parts of the world, including Brazil. 

Celebrating this growth, Carmen’s will launch at the Multidisciplinary Pain Congress, Pain Brazil 2022, which takes place from June 22 to 24 in Campinas, SP, its newest line of pure cannabis extract products, which contain all the beneficial components of the plant in their formulation. 

Despite having a full spectrum formulation, the highlight of the new product lies in the concentration of three major components: THC, CBD, and CBG.    

Tetrahydrocannabinol, also known as THC, is one of the main cannabinoids found in cannabis. Once in the body, the compound interacts with the endocannabinoid system by binding to CB1 and CB2 receptors, providing analgesic action, alleviating symptoms of chronic and neuropathic pain. Additionally, it has other properties, such as anticancer, antioxidant, anti-inflammatory, and bactericidal actions.

CBG (cannabigerol) acts on the maintenance potential of receptors and promotes better absorption and receptivity of all cannabinoids, making their therapeutic action more effective. 

CBD (cannabidiol), the most well-known cannabinoid, has neuroprotective, anti-inflammatory, antidepressant, and analgesic actions. Together, THC, CBG, and CBD have the ability to enhance the therapeutic effects of the plant, as well as modulate the possible adverse actions of THC. 

What is the product's differential?

We already know that cannabis compounds act beneficially in our bodies, but how can we enhance these effects? Carmen’s found the answer to this question in the product's concentration. 

The new line comes with a novelty. Currently, most products sold in Brazil have a THC concentration of less than 0.3% due to psychoactive effects. However, the pharmaceutical's unprecedented formulation promises to bring all the benefits of the compound without causing unwanted reactions, due to the entourage effect, which is nothing more than the result of the interaction of terpenes, canaflavins, and phytocannabinoids from cannabis when entering the human body. In other words, by mixing the major compounds with some terpenes, the company has achieved good health results for patients without the adverse effects of the active compound, in this case, THC.

To clarify, the concentrations of the new medications are:

30ml Bottles

THC Dominant:

9% THC = 2700mg

3.5% CBD = 1050mg

2% CBG = 600mg

Balanced THC:

3% THC = 900mg

3% CBD = 900mg

2% CBG = 600mg

Terpenes:

< 3% of Myrcene

< 3% of Beta-caryophyllene

< 2% of Linalool

< 1% of Limonene

< 1% of Alpha-pinene

For which diseases can the new products be used?

According to the pharmaceutical company, the new products are widely indicated for pain. Additionally, the THC Dominant, due to its analgesic action, can also be prescribed for patients with neurological diseases such as Parkinson's, Alzheimer's, Multiple Sclerosis, and those undergoing chemotherapy. The Balanced THC, due to its anti-inflammatory action, is indicated for dental patients, in women's health treatment, and for psychiatric disorders. 

To learn more about Carmen’s, visit: 

www.carmensmed.com

Also, check out the company's institutional video: